This is the authors' abstract. We don't add key points for this paper.
The severe combined immunodeficiency (SCID) mouse was investigated as a model system to study the growth and immunogenicity of human gliomas. Human glioma cell lines U-251MG, KNS-42, SF-188, A-172, and T-98G were injected subcutaneously into SCID mice. The cell lines U-251MG and KNS-42 grew as large, subcutaneous masses; SF-188, A-172, and T-98G did not grow. Glioma-immune system interactions were studied by the transplantation of human peripheral blood lymphocytes into tumor-bearing SCID mice. In the resultant SCID-human (SCID-hu) mice, transplanted lymphocytes infiltrated into the subcutaneously growing tumors and expressed the surface markers of human B, T, and natural killer cells. The SCID-hu mouse is a potentially powerful model to study the basic tumor biology of some human gliomas and also represents a useful screening system to evaluate experimental immunotherapies for brain tumors.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Sawa et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: